IMMUNITYBIO, INC. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations
IMMUNITYBIO, INC. (IBRX) had Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations of $76.95 million as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations · last filed 2026-08-04
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations $76.95M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations $206.47M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations $89.43M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations $61.34M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations as first filed |
|---|---|---|
| 2026-06-30 | $76.95M 10-Q · filed 2026-08-04 | |
| 2026-03-31 | $206.47M 10-Q · filed 2026-05-07 | |
| 2025-12-31 | $89.43M 10-Q · filed 2026-08-04 | |
| 2025-09-30 | $61.34M 10-Q · filed 2025-11-05 | |
| 2025-06-30 | $138.14M 10-Q · filed 2026-08-04 | |
| 2025-03-31 | $61.14M 10-Q · filed 2026-05-07 | |
| 2024-12-31 | $143.91M 10-Q · filed 2026-08-04 | |
| 2024-09-30 | $112.30M 10-Q · filed 2025-11-05 | |
| 2024-06-30 | $130.44M 10-Q · filed 2025-08-05 | |
| 2024-03-31 | $133.37M 10-Q · filed 2025-05-12 | |
| 2023-12-31 | $265.79M 10-K · filed 2026-02-23 | |
| 2023-09-30 | $178.30M 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $43.83M 10-Q · filed 2024-08-12 | |
| 2023-03-31 | $88.81M 10-Q · filed 2024-05-09 | |
| 2022-12-31 | $104.97M 10-K · filed 2026-02-23 | |
| 2022-09-30 | $104.48M 10-Q · filed 2023-11-09 | |
| 2022-06-30 | $62.22M 10-Q · filed 2023-08-08 | |
| 2022-03-31 | $36.56M 10-Q · filed 2023-05-11 | |
| 2021-12-31 | $181.28M 10-K · filed 2025-03-03 | |
| 2021-09-30 | $64.70M 10-Q · filed 2022-11-09 | |
| 2021-06-30 | $84.14M 10-Q · filed 2022-08-08 | |
| 2021-03-31 | $44.86M 10-Q · filed 2022-05-10 | |
| 2020-12-31 | $35.09M 10-K · filed 2024-03-19 | $11.62M 10-K · filed 2021-03-04 |
| 2020-09-30 | $84.86M 10-Q · filed 2021-11-12 | $27.87M 10-Q · filed 2020-11-09 |
| 2020-06-30 | $115.34M 10-Q · filed 2021-08-12 | $102.88M 10-Q · filed 2020-08-07 |
| 2020-03-31 | $58.83M 10-Q · filed 2021-05-14 | $17.13M 10-Q · filed 2020-05-11 |
| 2019-12-31 | $75.98M 10-K · filed 2023-03-01 | $15.69M 10-K · filed 2020-03-25 |
| 2019-09-30 | $18.47M 10-Q · filed 2020-11-09 | |
| 2019-06-30 | $17.71M 10-Q · filed 2020-08-07 | |
| 2019-03-31 | $23.66M 10-Q · filed 2020-05-11 | |
| 2018-12-31 | $95.28M 10-K · filed 2022-03-01 | $17.00M 10-K · filed 2019-03-13 |
| 2018-09-30 | $15.49M 10-Q · filed 2019-11-05 | |
| 2018-06-30 | $16.30M 10-Q · filed 2019-08-06 | |
| 2018-03-31 | $11.38M 10-Q · filed 2019-05-08 | |
| 2017-12-31 | $24.05M 10-K · filed 2021-03-04 | |
| 2016-12-31 | $8.26M 10-K · filed 2020-03-25 | |
| 2015-12-31 | $176.09M 10-K · filed 2019-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |